Talimogene Laherparepvec (T-VEC) is a first-in-class oncolytic virus that mediates local and systemic anti-tumor activity by direct cancer cell lysis and an "in situ vaccine" effect. Based on an increased durable response rate compared to granulocyte macrophage-colony stimulating factor (GM-CSF) in a randomized phase 3 trial , it was approved by the FDA for the treatment of melanoma metastatic to skin or lymph nodes. The drug is currently in clinical trials as monotherapy and in combination with immune-checkpoint inhibitors and radiation in melanoma and other cancers. The mechanism of action, toxicity, and efficacy as well as its role in current clinical practice and potential future applications will be reviewed.
Introduction
Novel systemic treatment modalities such as inhibition of the immune checkpoints Cytotoxic TLymphocyte Antigen 4 (CTLA-4) and Programmed Death-1 (PD-1)/PD-L1 as well as BRAF and MEK inhibition have expanded the range of therapeutic modalities for advanced melanoma (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . The anti-tumor activity of both MAPK pathway targeted therapy (for BRAF V600 mutant melanoma) and immune checkpoint inhibition (independent of a BRAF mutation) with response rates of 60% and higher is striking and has improved the prognosis for many patients. Both CTLA-4 and/or PD1/PD-L1 blockade with monoclonal antibodies can achieve durable clinical benefit suggesting that endogenous tumor directed T cell responses, suppressed by inhibitory pathways such as CTLA-4 and/or PD-1/PD-L1, can be invigorated resulting in affective tumor control(1, 2, 10-13). Many patients experience primary or secondary resistance to PD-1 and/ or CTLA-4 inhibition. Alternative treatments for these patients are therefore still urgently needed.
Talimogene laherparepvec (T-VEC), an agent with a different and potentially complementary mechanism of action to immune checkpoint blockade is a recent addition to the therapeutic armamentarium for patients with advanced melanoma.
Mechanism of Action
T-VEC is an intralesionally delivered oncolytic immunotherapy comprised of a genetically engineered attenuated herpes simplex virus type 1 (HSV-1) of the JS-1 strain. TVEC invades both cancerous and healthy cells, but can only replicate in cancer cells, where it secretes granulocyte macrophage-colony stimulating factor (GM-CSF) in the process. The genes encoding neurovirulence infected cell protein 34.5 (ICP34.5) and the infected cell protein 47 (ICP47) are functionally deleted in the virus, while the gene for human GM-CSF is inserted. ICP 34.5 is required for viral replication in normal cells, which is mediated by interaction with proliferating cell nuclear antigen (PCNA) (14) whereas cancer cells proliferate independently of ICP34.5 expression. ICP47 is critical for the evasion of HSV-infected cells from cytotoxic T cells by interfering with peptide processing and presentation on MHC-1 (15) . Deletion of ICP47 in TVEC prevents potentially limited viral antigen presentation, which could compromise its function as an in situ vaccine. ICP47 deletion also leads to increased expression of the US11 gene, resulting in increased virus replication in cancer cells without decreasing tumor selectivity.
GM-CSF is a pro-inflammatory cytokine that promotes the recruitment and maturation of dendritic cells (DCs) as well as macrophages into potent antigen presenting cells, leading to priming of tumor specific T cells (16) . It has been used successfully as an immune adjuvant in many cancer vaccines.
TVEC has 2 distinct mechanisms of action: the lytic function of the virus destroys tumor cells directly, whereas the lysis of the cancer cells leads to release of tumor antigens, virus, and GM-CSF, attracting DCs thereby creating an in situ vaccine (Fig. 1) . In a subcutaneous murine melanoma model, tumor growth inhibition on the contralateral, uninjected site was only seen when TVEC contained GM-CSF, establishing a systemic effect of the lytic virus that is likely mediated by a host immune response (17, 18) .
Clinical Development
Research. 
Phase 1
In a phase 1 study, 30 patients with previously treated melanoma, breast cancer, gastric adenocarcinoma, or head and neck cancer who had cutaneous or subcutaneous lesions accessible for injections were treated with different doses and schedules of T-VEC (19) . The most common adverse events were grade 1 fever, constitutional symptoms, nausea, anorexia, and injection site reactions. One patient was reported to experience grade 2 fever, rigor, hypotension, tachycardia, and constitutional symptoms. Overall, the toxicities were more intense in HSV-seronegative patients; an initial low-dose of T-VEC, leading to HSV seroconversion, followed by a series of higher dose injections was better tolerated. There were no partial or complete responses, however flattening of both injected and non-injected metastases was seen in 6 of 26 evaluable patients. Post-treatment biopsies of injected lesions demonstrated inflammation and necrosis.
Phase 2
Fifty patients with unresectable stage IIIC -IV melanoma with one or more injection accessible tumor lesion were enrolled on a phase 2 study, assessing response rate, survival, and safety of T-VEC (20) . Thirty seven (74%) of the patients had received prior systemic therapy and 20 (40%) had M1c visceral disease. Based on the experience from the phase 1 study, patients received intratumoral injections of up to 4 mL of 10 6 pfu/mL of T-VEC, 
Phase 3
In a phase 3 study, 436 patients with unresected stage IIIB to IV melanoma were randomized at a 2:1 ratio to receive TVEC versus subcutaneously administered GM-CSF (22) . T-VEC or GM-CSF was administered until CR, clinically significant progressive disease (PD), intolerable side effects, or 12 months of therapy without an objective response. As in the phase 2 study, T-VEC was initially administered at10 6 pfu/mL for seroconversion, whereas subsequent doses were given at 10 8 pfu/mL 3 weeks after the first dose and then every 2 weeks. T-VEC injection was restricted to cutaneous and subcutaneous metastases; different lesions could be prioritized for injection differently at any visit depending on size and emergence of new lesions. GM-CSF was given daily subcutaneously at 125μg/m 2 during the first 14 days of a 28 day cycle; it was chosen as a comparator arm based on overall survival benefit compared to historical control observed in a previous study in melanoma patients at high risk for recurrence (23) . The primary endpoint was durable response rate (DRR) defined as PR or CR with an onset during the first 12 months of treatment and lasting for at least 6 months. Secondary endpoints included overall survival, best overall response, and duration of response. Approximately half of the patients in each arm were previously untreated; 45% of patients in the T-VEC arm and 39% of patients in the GM-CSF arm were stage IVM1b/c. The study met its primary endpoint: DRR was significantly higher in the T-VEC arm (16.3%) compared with the GM-CSF arm (2.1%). The overall response rate was also significantly increased in the TVEC arm (26.4%) compared to GM-CSF alone (5.7%) as was the number of CRs (10.8% vs. 1%). Median overall survival (OS) was 23.3 months in the T-VEC arm and 18.9 months in the GM-CSF arm (HR, 0.79; 95%CI, 0.62 -1.00; p=0.051) and it was therefore unclear, at least from the primary study analysis, whether T-VEC was associated with improved OS.
Subgroup analyses showed higher anti-tumor activity of T-VEC in patients with stage IIIB, IIIC, and IVM1a disease: with T-VEC, DRR was 33% in patients with IIIB or IIIC and 16% in patients with stage IVM1a, respectively compared to 0% and 2% with GM-CSF. In contrast, DRR was 3 and 7% in patients with stage IVM1b and M1c disease who received T-VEC compared to 4% and 3% in patients who received GM-CSF. Furthermore, the improved efficacy of T-VEC over GM-CSF was predominantly seen in treatment-naive patients.
The treatment was overall well tolerated: the most common toxicities included injection site reactions, fatigue, chills, and fever and were in line with previous experience from phase 1 and 2 trials. The only ≥ 3 toxicity that occured in ≥ 2% of patients was cellulitis; other grade 3 or 4 toxicities included fatigue, extremity pain, vomiting, injection site pain, edema, and extremity independent of BRAFV600 status. While TVEC was developed and the registration trial OPTIM-3 designed and largely conducted in a "pre-checkpoint inhibition, pre-MAPK pathway inhibition era," the recent FDA approval places the drug in a vastly different therapeutic landscape for advanced melanoma. Nevertheless, despite the availability of a number of effective drugs for melanoma, the approval of another drug with an entirely different mechanism of action is welcome, both for standard of care treatment and current as well as future investigations. Given TVEC's benign toxicity profile, the durability of tumor responses, the requirement for the presence of skin metastases, and the efficacy in stage IIIB,C and IVM1a disease, the drug appears as an attractive choice for 1) "slow growing" lymph node, in transit or distant skin metastases, e.g. patients who had several resections in the past and are no longer deemed resectable 2) BRAF wild-type patients who have unequivocally progressed on PD-1 and/or CTLA-4 inhibition; 3) BRAF wild type patients with multiple comorbidities or autoimmune disease who are not deemed good candidates for immune checkpoint inhibition.
Since the drug is a live, genetically engineered virus that actively replicates in the host, special attention needs to be given with regards to healthcare provider and patient education, transmission precautions, and environmental safety.
Current and Future Clinical Development
Multiple clinical trials are ongoing assessing T-VEC in melanoma in the neoadjuvant setting as well as in the metastatic setting with a focus on correlative studies such as analysis of talimogene laherparepvec DNA in blood and urine as well as T cell tumor infiltration prior and after and PD-1 inhibition also showed synergy with a novel material engineered scaffold vaccine that co-delivers autologous tumor lysate, GM-CSF and the TLR-9 agonist CPG with precise spatial and temporal control (27) . Recently reported preliminary efficacy data from an ongoing study combining T-VEC and the anti-CTLA antibody ipilimumab appear to support synergy between the 2 agents: 10 of 17 evaluable patients (56%) had an objective response including 6 CRs and 4
PRs, which is substantially higher than what would be expected from either of the drugs alone (28) . The combination of T-VEC and the PD-1 inhibitor pembrolizumab are underway in melanoma and head and neck cancer (Table 1) Research.
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